A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
PARP inhibitors have clinically demonstrated good antitumor activity in patients with BRCA mutations. Here, we described YHP-836, a novel PARP inhibitor, YHP-836 demonstrated excellent inhibitory activity for both PARP1 and PARP2 enzymes. It also allosterically regulated PARP1 and PARP2 via DNA trap...
Saved in:
Main Authors: | Tingting Du (Author), Zhihui Zhang (Author), Jie Zhou (Author), Li Sheng (Author), Haiping Yao (Author), Ming Ji (Author), Bailing Xu (Author), Xiaoguang Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells
by: Cathy Su, et al.
Published: (2017) -
Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
by: Chuanlin Wang, et al.
Published: (2022) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018) -
Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
by: Natalie Shammas, et al.
Published: (2022) -
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
by: Anastasia Navitski, et al.
Published: (2021)